CONTINEUM THERAPEUTICS INC-A

CTNMNASDAQ

🏆 #2626 by market capEarnings Oct 29US Equity

$14.87▲ $0.04 (+0.30%)

Live

1h▼ 1.2%

24h▲ 0.3%

7d▼ 2.7%

14d▲ 3.4%

30d▲ 1.9%

1y▲ 119.2%

🏦Market Cap

$556M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $14.79 – $15.02
52-Week Range: $6.19 – $16.91
Volume: $3.67B
Avg Volume: $4.32B
Shares Outstanding: 37.4M
Next Earnings: Oct 9, 2026

Fundamentals Snapshot

Annual Revenue: $150M
Last Q Revenue: $36M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.95
Dividend Yield: —

Why Investors Own CTNM

✓High-growth profile — revenue up +56.0% YoY with expanding US Equity exposure.
✓Healthy economics — 52% gross margin and 16% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$150M▲ +55.0% YoY

Gross Margin (TTM)

52.1%▼ −0.4% YoY

Operating Income (TTM)

$40M▲ +55.0% YoY

Free Cash Flow (TTM)

$24M▲ +55.0% YoY

About CONTINEUM THERAPEUTICS INC-A

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

🦦